Current Hepatic Encephalopathy Therapies Targeting Gut-Liver Axis Disturbance

Author(s):

Pamela Kushner, MD, FAAFP ,Nancy Reau, MD

Nancy Reau, MD, leads a discussion on the current abnormality-targeting agents used to prevent and treat hepatic encephalopathy (HE) by addressing the gut-liver axis, specifically focusing on lactulose or lactitol and rifaximin, while also explaining their mechanisms of action and adverse event profiles.

EP: 1.Exploring the Impact of Hepatic Encephalopathy on Patients and Their Families

EP: 2.Educating Primary Care Clinicians on Outpatient HE Management and Ammonia Testing

EP: 3.HE Experts on Symptoms, Risk Factors, Diagnosis Challenges, and Severity Grading

EP: 4.Collaborating with Specialists: Primary Care Clinician’s Evolving Role in HE Management

EP: 5.Preventing Cirrhosis Progression: Gut-Liver Axis, Circulation, Inflammation

EP: 6.Hepatic Encephalopathy: Exploring Alterations in Microbiota Caused by Liver Disease

Now Viewing

EP: 7.Current Hepatic Encephalopathy Therapies Targeting Gut-Liver Axis Disturbance

EP: 8.AASLD Guidelines for Hepatic Encephalopathy: Rifaximin's Role and Safety

EP: 9.Overview of Outpatient Strategies for Optimizing Patient Outcomes in HE

EP: 10.Managing Adverse Effects in HE Treatment

EP: 11.Practical Tips for the Primary Care Clinician Treating HE

EP: 12.Refractory Encephalopathy, Multivitamins and Closing Thoughts

Which agents do we have to target abnormalities in gut-liver axis to prevent and treat HE? (lactulose or lactitol, rifaximin) Sanchez-Delgado et al 2016
- What is the mechanism of action of these therapies?
- What is their tolerability and their side effect profile?